Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Impedimed Limited ( (AU:IPD) ) has provided an announcement.
ImpediMed Limited has released its preliminary final report for the financial year ending June 30, 2025, showing a 23% increase in revenue to $12.7 million. Despite this growth, the company reported a 17% increase in losses, amounting to $23.2 million, and did not declare any dividends. The report highlights a decrease in net tangible assets per security from 1.22 cents to 0.37 cents, indicating potential challenges in financial stability. These results may impact the company’s market positioning and stakeholder confidence as it continues to navigate the competitive medical technology landscape.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, specializing in the development and sale of non-invasive medical devices that measure, monitor, and manage fluid status and tissue composition. The company’s primary products focus on providing solutions for healthcare providers to improve patient outcomes, particularly in areas such as lymphedema and heart failure management.
Average Trading Volume: 2,554,679
Technical Sentiment Signal: Sell
Current Market Cap: A$89.31M
Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.